Eribulin mesylate

Sarika Jain, Linda T. Vahdat*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations


Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U.S. Food and Drug Administration as third-line treatment of metastatic breast cancer refractory to anthracyclines and taxanes. Eribulin is a synthetic analogue of halichondrin B, which inhibits microtubule polymerization by a mechanism distinct from other available antitubulin agents. Eribulin significantly increased overall survival (OS; median OS for the eribulin-treated group was 13.1 months versus 10.6 months for the group treated by investigator's choice) in a heavily pretreated metastatic breast cancer population. Eribulin has a manageable side-effect profile, notably neutropenia and fatigue, and a relatively low incidence of peripheral neuropathy. The mechanism of action, pharmacokinetics, preclinical antitumor activity, and clinical trials of eribulin in the metastatic breast cancer setting are reviewed here.

Original languageEnglish (US)
Pages (from-to)6615-6622
Number of pages8
JournalClinical Cancer Research
Issue number21
StatePublished - Nov 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Eribulin mesylate'. Together they form a unique fingerprint.

Cite this